DEPARTMENT OF MODERN TECHNOLOGIES OF MEDICAL DIAGNOSTICS AND TREATMENT
Scientific work
The staff of the department is actively involved in scientific work. The research is performed on the basis of the Research Institute of Experimental and Clinical Medicine.
From the materials of the report of 2019
The list of research performed in the department
| № | Theme code
(applied, fundamental) |
№ state registration | Name of the scientific research work (SRW) | Deadlines | SRW leaders | Responsible performers |
| SRW financed by the Ministry of Health of Ukraine from the State Budget | ||||||
| 1. | Applied SRW | 0118U001214 | To study the importance of genetic factors and external influences on the development and progression of microcirculatory complications in type 2 diabetes | 2018-2020 | Natrus LV | Panova TI |
| 2. | Applied SRW | 0118U001218 | Improving methods of diagnosis, treatment and secondary prevention of complications in patients with metabolic syndrome and gout based on the study of the type of immune response, the activity of adhesion and aggregation of immunocompetent cells and the functional state of the endothelium | 2018-2020 | Natrus LV,
Kondratyuk VE |
Maltsev DV |
| 3. | Fundamentally | Study of cell-molecular mechanisms of pharmacological influence on the reprogramming of the functional phenotype of macrophages in wound regeneration on the background of hyperglycemia | 2019-2021 | Natrus LV | Panova TI | |
| 4. | Fundamentally | Structural and functional changes of neurons of the medio-basal hypothalamus in disorder of carbohydrate and lipid metabolism | 2019-2021 | Tchaikovsky Yu.B. | Natrus LV | |
| SRW financed on the basis of economic agreements, including clinical trials | ||||||
| 1. | № 253 | Clinical trials of allergy blot “Respiratory profile” | 2019 | Natrus LV | Maltsev DV | |
| 2. | № 273 | Clinical trials of allergological blot “Food profile 1” “Multiplex” | 2019-2020 | Natrus LV | Maltsev DV | |
Information on received grants
| № | The name of Grant sponsor | Grant receiver (surname, initials) | Grant purpose | Grant effectiveness (for example: participation in a conference) |
| 1. | Octapharma AG | Bogomolets National Medical University | Study “Effectiveness of Octaplas replacement therapy for primary leucine deficiency (MBL) of mannose” | The effectiveness of Octaplas replacement therapy for primary leucine deficiency (MBL) of mannose in patients has been studied |
List of applications for inclusion of a scientific report in the List of scientific (scientific and technical) products intended for the implementation of medical science achievements in the field of health care in the reporting year and monitoring of the implementation of scientific products for 3 years
| № | Name of innovation (registration №) | Name of clinical unit or laboratory (developer) | Healthcare facilities where innovations have been implemented for 3 years | Implementation efficiency (medical, economic, social) |
| 1. | Information sheet “Method of assessing the state of platelet hemostasis for reconstructive treatment with enriched with growth factors plasma according to the method of PRGF ENDORET” | Research Institute of Experimental and Clinical Medicine | 2018 – Department of Surgical Dentistry of the Dental Medical Center (implementation act dated 19.11.2018),
Kyiv City Clinical Ambulance Hospital: Department of Neurosurgery (implementation act dated 19.11.2018) |
Implemented in specialized health care facilities (regional, city, district), maxillofacial surgery and dentistry for post-traumatic and postoperative defects and reconstructive treatment. |
| 2. | Guidelines
The method of using enriched with growth factors plasma according to the method of PRGF EndoRet, taking into account the assessment of platelet hemostasis. |
Research Institute of Experimental and Clinical Medicine | 2018 – Department of Surgical Dentistry of the Dental Medical Center (implementation act dated 19.11.2018),
Kyiv City Clinical Ambulance Hospital: Department of Neurosurgery (implementation act dated 19.11.2018) |
For implementation in institutions of maxillofacial surgery and stomatology concerning posttraumatic and postoperative defects and reconstructive and restorative treatment |
| 3. | Protocol of clinical trials on the effectiveness, sensitivity, specificity and safety of medical devices (hereinafter – VMP): A set of reagents for the determination of IgE antibodies to respiratory allergens in human serum (plasma), “Respiratory profile” manufactured by Limited Liability Company “Product SEVEN », Ukraine | Research Institute of Experimental and Clinical Medicine | 2019 – clinical diagnostic laboratories to improve diagnostic approaches in the field of allergy diagnostics. | Medical device: A set of reagents for the determination of IgE antibodies to respiratory allergens in human serum (plasma), “Respiratory profile” produced by Limited Liability Company “Production Company SIMESTA” (Ukraine) does not require additional research, laboratory characteristics (parameters) meet requirements for their use in medical and diagnostic practice and are not inferior in quality to analogues of leading European manufacturers approved for use in Ukraine. The product can be used in the medical industry of Ukraine. |
| 4. | Protocol of clinical trials on the effectiveness, sensitivity, specificity and safety of medical devices (hereinafter – VMP): A set of reagents for the determination of IgE antibodies to respiratory allergens in human serum (plasma), “Food Profile 1” produced by the Limited Liability Company “Production SIMESTA company », Ukraine | Research Institute of Experimental and Clinical Medicine | 2019 – clinical diagnostic laboratories to improve diagnostic approaches in the field of allergy diagnostics. | Medical device: A set of reagents for the determination of IgE antibodies to respiratory allergens in human serum (plasma), “Respiratory profile” produced by Limited Liability Company “Production Company SIMESTA” (Ukraine) does not require additional research, laboratory characteristics (parameters) meet requirements for their use in medical and diagnostic practice and are not inferior in quality to analogues of leading European manufacturers approved for use in Ukraine. The product can be used in the medical industry of Ukraine. |
Key publications in 2020
- Natrus L.V., Ryzhko I.M., Lisakovskaya O.O., Tikhomirov A.O., Labudzynsky D.O., Panova T.I. The role of NF-κB in the differentiation and activation of neutrophils during the healing of burn wounds in the skin of rats. Physiol. magazine. 2019; 65 (6): 94-105. DOI: https://doi.org/10.15407/fz65.06.094
- Natrus L.V., Gayova L.V., Byhovets M.Yu., Osadchuk Yu.S., Konovalov S.E. The value of regulatory effects on lipid metabolism in during complicated diabetes mellitus. Fiziol. Zh. 2020; 66(1): 25-34. DOI: https://doi.org/10.15407/fz66.01.025
- Brodetska, L., Natrus, L., Lisakovska, O. et al. The regulatory role of the RANKL/RANK/OPG signaling pathway in the mechanisms of tooth eruption in patients with impacted teeth. BMC Oral Health 20, 261 (2020). https://doi.org/10.1186/s12903-020-01251-y
- O. Rykov, L.V. Natrus, M.Iu. Bykhovets. PPARγ-mediated differences in energy substrate among T2DM patients differing in the stage of diabetic retinopathy . Journal of Ophthalmology (Ukraine) – 2019 – Number 6 (491) http://www.ozhurnal.com/sites/default/files/2019-6-2.pdf
- Labudzynskyi D. O., Shymanskyi I. O., Lisakovska O. O., A. O. Mazanova, Natrus L. V., Veliky M. M. Vitamin D(3) regulates hepatic VEGF-A and apelin expression in experimental type 1 diabetes. Ukr.Biochem.J. 2020; Volume 92, Issue 4, Jul-Aug, pp. 5-13. http://ukrbiochemjournal.org/2020/09/vitamin-d3-regulates-hepatic-vegf-a-and-apelin-expression-in-experimental-type-1-diabetes.html
- Maltsev D., Natrus L. The Effectiveness of Infliximab in Autism Spectrum Disorders Associated with Folate Cycle Genetic Deficiency. Psychiatry, psychotherapy and clinical psychology, 2020, Vol 11, (3). Р 581-592. DOI 10.34883/PI.2020.11.3.015 (the article is in print)
